tiprankstipranks
Arovella Therapeutics Limited (AU:ALA)
:ALA

Arovella Therapeutics Limited (ALA) Price & Analysis

Compare
12 Followers

ALA Stock Chart & Stats


---

Financials

Quarterly

Options Prices

Currently, No data available
---

Ownership Overview

1.02%98.98%
Mutual Funds
― Other Institutional Investors
98.98% Public Companies and
Individual Investors

ALA FAQ

What was Arovella Therapeutics Limited’s price range in the past 12 months?
Arovella Therapeutics Limited lowest share price was AU$0.08 and its highest was AU$0.21 in the past 12 months.
    What is Arovella Therapeutics Limited’s market cap?
    Arovella Therapeutics Limited’s market cap is AU$95.89M.
      When is Arovella Therapeutics Limited’s upcoming earnings report date?
      Arovella Therapeutics Limited’s upcoming earnings report date is Aug 27, 2025 which is in 145 days.
        How were Arovella Therapeutics Limited’s earnings last quarter?
        Arovella Therapeutics Limited released its earnings results on Feb 26, 2025. The company reported -AU$0.001 earnings per share for the quarter, beating the consensus estimate of -AU$0.002 by AU$0.001.
          Is Arovella Therapeutics Limited overvalued?
          According to Wall Street analysts Arovella Therapeutics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Arovella Therapeutics Limited pay dividends?
            Arovella Therapeutics Limited does not currently pay dividends.
            What is Arovella Therapeutics Limited’s EPS estimate?
            Arovella Therapeutics Limited’s EPS estimate is >-0.01.
              How many shares outstanding does Arovella Therapeutics Limited have?
              Arovella Therapeutics Limited has 1,183,870,600 shares outstanding.
                What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?
                Arovella Therapeutics Limited reported an EPS of -AU$0.001 in its last earnings report, beating expectations of -AU$0.002. Following the earnings report the stock price went down -30%.
                  Which hedge fund is a major shareholder of Arovella Therapeutics Limited?
                  Currently, no hedge funds are holding shares in AU:ALA
                  ---

                  Arovella Therapeutics Limited Stock Smart Score

                  Company Description

                  Arovella Therapeutics Limited

                  Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.
                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Opthea Limited
                  Cynata Therapeutics Limited
                  Immutep Ltd
                  Prescient Therapeutics Limited
                  Race Oncology Ltd.
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis